<DOC>
	<DOCNO>NCT00145366</DOCNO>
	<brief_summary>The trial protocol deal effect pretreatment rhTSH radioiodine treatment thyroid size function , patient nontoxic toxic nodular goiter . It introduction novel principle , base prospective , randomize double blind investigation . Attached , investigate acute effect rhTSH thyroid size ( measure ultrasonography ) , healthy individual patient nontoxic nodular goiter . Thus , investigation divide 4 category list : 1 . Prospective randomize double blind study pretreatment 0.3 mg recombinant human TSH effect radioiodine nontoxic multinodular goiter . 2 . Prospective randomize double blind study pretreatment 0.3 mg recombinant human TSH effect radioiodine thyroid size function patient large ( &gt; 100 ml ) nontoxic toxic goiter . 3 . Does administration 0.9 mg recombinant human TSH affect thyroid function volume healthy individual ? A randomized double-blind cross-over trial . 4 . Does administration 0.3 mg recombinant human TSH affect thyroid function volume healthy individual patient multinodular non-toxic goiter ? A randomized double-blind cross-over trial . As final note investigate , pilot-study ; 5 . The influence rhTSH thyroid radioiodine uptake patient hyperthyroidism treat continuous block-replacement therapy .</brief_summary>
	<brief_title>rhTSH , Thyroid Size , Radioiodine Therapy Benign Goiter</brief_title>
	<detailed_description />
	<mesh_term>Graves Disease</mesh_term>
	<mesh_term>Goiter</mesh_term>
	<mesh_term>Calcitonin</mesh_term>
	<criteria>Healthy volunteer intact thyroid gland Patients nontoxic/subtoxic nodular goiter confirm ultrasonography Patients toxic nodular goiter Patients Graves ' disease Treatment drug alter thyroid function size ( last 3 month prior inclusion ) Prior 131I treatment Alcohol , medicine drug abuse Pregnancy lactation No safe contraception Participation another clinical trial Allergic reaction towards rhTSH Fine needle biopsy without valid diagnostic criterion benign disease Suspicion malignancy , increase ionized serum calcium and/or serum calcitonin Incontinence Physically psychic condition hinders corporation Ischemic attack till 3 month inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Benign nontoxic toxic goiter</keyword>
	<keyword>rhTSH</keyword>
	<keyword>131I</keyword>
	<keyword>goiter reduction</keyword>
	<keyword>131I kinetic</keyword>
	<keyword>thyroid size</keyword>
	<keyword>patient satisfaction</keyword>
	<keyword>adverse effect</keyword>
	<keyword>BRT</keyword>
	<keyword>Graves ' disease</keyword>
</DOC>